Bionik Laboratories Corp. · OTC:BNKL
Bionik Laboratories — Investor Presentation (February 2017)
27 slides from Bionik Laboratories's investor presentation, Feb 27, 2017
Slide 1: Investor Presentation February 2017
Investor Presentation February 2017 www.bioniklabs.com OTCQX:BNKL Advanced robotic products for sufferers of neurological impairment
Slide 2: Legal Disclaimer
LEGAL DISCLAIMER This presentation contains forward - looking statements relating to future events or the future financial performance and operations of Bionik . Forward - looking statements, which involve assumptions and describe Bionik’s intent, belief or current expectations about its business op
Slide 3: Bionik Overview
3 BIONIK OVERVIEW • Founded in 2011 in Toronto - Initial focus - assistive technology • Acquired Interactive Motion Technologies (Boston - based) in 2016 - Founded by two world leaders in robotic technology from MIT - Industry leading patented technology and products • Proprietary product portfolio
Slide 4: Our Vision and Mission
OUR VISION AND MISSION There is a rapidly growing need for quality of life solutions for the millions of mobility challenged people, while reducing the financial burden to the society. Our goal is to be the market leader in evidence based rehabilitative and assistive robotic technologies from hospit
Slide 5: Investment Highlights
5 INVESTMENT HIGHLIGHTS Large & Growing Patient Population Emergence of Mobility Rehabilitation Robotics Bionik’s Technologies Already in Market Extensive Clinical Data Supporting Efficacy and Cost Savings Deep Product Pipeline: Hospital - > Home
Slide 6: Stroke Is a Global Epidemic
6 Source: Forecasting the Future of Stroke in the United States; Stroke; August 2013, Volume 44, Issue 8 Source: Global and regional burden of stroke during 1990 – 2010: findings from the Global Burden of Disease Study 2010; 18 January 2014, Volume 383, No. 9913 Global stroke incidence per 100,000 p
Slide 7: Significant Opportunity
7 SIGNIFICANT OPPORTUNITY 7 2018 2018 2017 US UNITS EUROPE UNITS ROW UNITS ANNUAL UNITS Average Selling Price TOTAL ADDRESSABLE ANNUAL MARKET (TAM) InMotion Clinic InMotion Home ARKE Home ARKE Clinic 1,620 1,620 4,860 8,100 225,000 225,000 450,000 900,000 30,000 30,000 60,000 120,000 540 540 1,620 2
Slide 8: Current In-Market Products
8 CURRENT IN - MARKET PRODUCTS InMotion ARM™ (FDA Cleared) - De si gne d t o r e hab ili t a t e s t r o k e p a t i e nt s w i t h uppe r body ne u r o l o g i c al li m i t a t i ons - Interactive t ec hno l o gy that continuously ada p t s and challen g es t h e p a t ie nt ' s abili t y - All o
Slide 9: Product Portfolio in Development
9 PRODUCT PORTFOLIO IN DEVELOPMENT • AR K E™ Exoskeleton - Lower extremity assistance for the neurologically impaired during inpatient stay - Assistance for the mobility impaired, in both the healthcare (neuro) and consumer (the aged) channels - Cloud analytics through strategic partnership with IBM
Slide 10: Product Portfolio Summary
10 PRODUCT PORTFOLIO SUMMARY PRODUCT DEVELOPMENT PRE - CLINICAL CLINICAL IN MARKET MILESTONE InMotion ARM In Market InMotion HAND In Market InMotion WRIST In Market InMotion AHW V2 Commercial Launch Q2 ’17 InMotion ANKLEBOT File FDA Clearance Q2 ’17 ARKE Lower Body Exoskeleton Complete 2.1 Clinical
Slide 11: Conventional vs Bionik Robots - Improved Outcomes
• Focuses on habitual movement – repetition of a few functional motor skills • Treatment protocols are non - reproducible • Difficult to quantify true recovery • Low intensity - 25 to 45 movements per session • Focuses on reducing impairment — neural plasticity and remapping of pathways • Reproducib
Slide 12: Clinically and Economically Proven
12 CLINICALLY AND ECONOMICALLY PROVEN • Over 200 published papers reviewing Bionik’s products • Over 1000 patients studied in clinical trials at prestigious academic and clinical sites • Demonstrated clinical and economically significant results compared to conventional therapy • Studies meet the hi
Slide 13: Bionik Clinical Data Prompts Treatment Guidelines
13 BIONIK CLINICAL DATA PROMPTS TREATMENT GUIDELINES • Referencing Bionik’s c li n i c a l tr ial s , AHA's S t r o k e Division assigned highest recommendation level for r o b o t a ssi s t e d t h e r a p y f o r upp er e x t r e m it y m o t o r r e habili t a t ion of moderate to severe s t r o
Slide 14: Expansion of Clinical Data (RATULS)
RATULS - Three arm randomized controlled trial designed to determine whether robot assisted training improves upper limb function post stroke compared to enhanced upper limb therapy or conventional therapy 720 s ub jec t s a c r o s s f ou r s t ud y ce nt r e s i n U n i t e d K i n g do m Pr i m a
Slide 15: The Bionik Advantage: A Proven Effect on Brain Plasticity
15 THE BIONIK ADVANTAGE: A PROVEN EFFECT ON THE BRAIN PLASTICITY S o u r c e:” R o b o t ic M e a s u r eme n t of A r m Mo v eme n t s Af t er St r o k e E s t a bli s h e s B i o m a r k e r s of M o t o r R ec o v er y. ” St r o k e jo u r n al of A H A January 2014, Volume 45, Issue 1 Circle Eva
Slide 16: U.S. Installations and High Profile Customers
Rehab Institute of Michigan Detroit, Michigan Frazier Rehabilitation Institute Louisville, Kentucky Baptist Medical System Memphis, Tennessee Texas State University San Marcos, Texas Cleveland Clinic Cleveland, Ohio Rancho Los Amigos Los Angeles, California VA Healthcare System Baltimore, Maryland F
Slide 17: International Customers and Partnerships
17 INTERNATIONAL CUSTOMERS AND PARTNERSHIPS Cardinal Santos Medical Center Philippines Rede de Reabilitação Lucy Montoro Hospital Brazil Australian NeuroRehabilitation Institute Australia McGill University Canada Fondazione Salvatore Maugeri Italy Guttman Institute Spain Queen Elizabeth Hospital Hon
Slide 18: Bionik Will Lead the Market
18 BIONIK WILL LEAD THE MARKET Hocoma Cyberdyne ReWalk Ekso Indigo Myomo Commercial strategies to expand access UK Study (2018) Bionik Bionik RehaTek Outcomes (Clinical Data) A cc e ss In - home products Broad product range Leverage clinical data Innovative revenue models S&M and d i s t ribu t i o
Slide 19: Commercial Strategy
19 1. Product Strategy – offer clinically proven products from hospital to home ▪ Improve existing clinical robot offering to make more appealing to commercial clinical decision makers ▪ Expand clinical robot offering into lower extremity – Anklebot , Gait Trainer and Arke ▪ Extend clinical robot of
Slide 20: Target Customers and Revenue Opportunity
5% cash pay patients • Inpatient rehab hospitals with high volume of stroke patients targeted for our clinical install expansion - 99% of stroke patients are discharged from Acute Care hospitals to Post Acute Care (PAC) settings - 1,100 Independent Rehab Facilities; 15,000 Skilled Nursing Facilities
Slide 21: Financial Snapshot
21 FINANCIAL SNAPSHOT - OTCQX: BNKL STOCK TICKER SYMBOL OTCQX: BNKL Market Capitalization as of February 24, 2017* $59.9 M Shares Outstanding* 96.4 M Warrants at exercise price of $1.40 16.4 M Warrants at exercise price of $0.80 1.2 M Cash as of December 31, 2016 $0.6 M Amount received in grants to
Slide 22: Growth Strategy
22 GROWTH STRATEGY • Building sales and distribution channels • Building new revenue models • Securing strategic investors and partners in key markets • Building pipeline organically and through licensing/acquisitions • Leveraging MIT relationships to expand product portfolio Expanded and Focused De
Slide 23: Management Team
23 • Peter Bloch, CPA, CA – Chief Executive Officer • Over 25 years of executive management experience with proven track record of building public and private technology companies . F ormer CFO and joint Interim CEO of Sanofi Canada, CFO of Intellivax, Gennum TSX:GNM (n/k/a Semtech NASDAQ:SMTC), Jus
Slide 24: Board of Directors and Key Advisors
24 Board of Directors • Dr. Robert Hariri • Independent Director • Chairman, Founder, Chief Scientific Officer, and former Chief Executive Officer of Celgene Cellular Therapeutics; Board member of Myos Corporation and Provista Diagnostics • Marc Mathieu • Independent Director • Chief Marketing Offic
Slide 25: Execution of Near-Term Priorities
Advance development products through to commercialization 25 Focus on revenue generation and market expansion Launch of AHW Version 2 InMotion product line Uplist to National Exchange (NASDAQ) EXECUTION OF NEAR - TERM PRIORITIES Advance distribution & development deals with potential Asian partners
Slide 26: Investment Summary
26 INVESTMENT SUMMARY • Proprietary robotics product line focused on stroke rehabilitation and assistive technology solutions from hospital to home • Proven clinical evidence differentiates product portfolio and puts Bionik in a leading position for reimbursement • Positioning to lead emerging marke
Slide 27: Contact
27 Phone + 1.416.640.7887 IR Contact jtc@jenenethomascommunications.com Headquarters 483 Bay Street, Office N105 Toronto, ON M5G 2C9 Canada www.bioniklabs.com OTCQX:BNKL
Bionik Laboratories — Investor Presentation (February 2017) on 6ix